The development of safe and effective drugs for analgesia and sedation has been one of the cornerstones in the development of critical care. The use of these agents has allowed for mechanical ventilation, invasive monitoring, and the performance of bedside procedures that would have previously required transport to the operating room. In the discipline of neurocritical care, these drugs are also regarded as important in controlling the cerebral metabolic rate of oxygen consumption (CMRO 2 ), cerebral blood fl ow (CBF), and intracranial pressure (ICP). Although the use of deep levels of sedation or a medically induced coma may be benefi cial in some populations of neurologically compromised patients, it has become clear that high doses of these drugs, particularly if administered as continuous infusions for prolonged periods, are associated with signifi cant deleterious outcomes in intensive care unit (ICU) survivors. Many of these drugs have been associated with increased incidence of delirium in ICU patients, which is a significant and independent indicator of length of time mechanically ventilated, ICU length of stay, hospital length of stay, impaired cognitive and functional outcomes after discharge, and mortality. Likewise, there is growing evidence that minimizing patient exposure to sedation and allowing for awakenings in the ICU has benefi ts for patient care. The medical/surgical ICU literature has demonstrated that seemingly simple RN-and RT-driven protocols such spontaneous daily breathing trials (SBTs) can decrease the mean length of mechanical ventilation by 2 days. This was followed by a spontaneous daily awaking trial (SAT) and an SAT and SBT that resulted in a median 4-day decrease in the length of mechanical ventilation. This combined SAT and SBT RN/RT-driven protocol is the most effective predictor of successful weaning from mechanical ventilation and subsequent extubation.
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With increasing rates of ICU survival, it is clear that many of our patients are being discharged with other serious problems. Up to 44% of patients who have received prolonged courses of continuous infusions of opioids may display long-term dependence on these drugs. Many of our patients are also experiencing postdischarge symptoms consistent with posttraumatic stress disorder or are being discharged with signifi cant functional and cognitive impairment independent of their initial diagnosis.
In critical care, fewer drugs and careful selection of drugs for analgesia and sedation are critically important to patient outcomes. The concept of analgosedation is to assess the patient's comfort, treat pain fi rst, and judiciously use sedative hypnotics if necessary to control anxiety and agitation. The Society for Critical Care Medicine has published up-todate guidelines for the management of pain, agitation, and delirium in the ICU. Information is also available from www.icudelirium.org. This article reviews some of the information contained within these recommendations and other literature pertinent to the practice of neurocritical care.
Pain
Pain is clinically defi ned as the unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage. Assessing and treating pain is the fi rst line in the management what has been termed analgosedation, minimizing the effects of pain while being able to maintain a lower level of sedation. The incidence of unreported and underreported pain in medical/ surgical ICU survivors as recalled at the time of discharge is greater than 50%. ICU survivors have also identifi ed pain as the leading cause of sleep disturbance while in the ICU. Up to 82% of survivors recall pain from the endotracheal tube, and 77% of these patients report experiencing the level of pain as moderate to severe in intensity. Although a true causal relationship is diffi cult to prove, up to 18% of survivors are at high risk for developing posttraumatic stress disorder.
Ideally, the gold standard for measuring pain in the hospital setting has been the use of a numeric rating scale such as the Visual Analog Scale that assigns a severity level of pain from 0 (no pain) to 10 (the most severe pain possible). Although some ICU patients, both nonintubated and intubated, may be able to use such a scale in a reproducible and validated fashion, many critically ill and neurologically compromised patients are unable to do so. Sedation, encephalopathy, aphasia, neuromuscular blockade, and concomitant systemic illness have led to the use of surrogate markers of pain. Unfortunately, markers such as elevated blood pressure, heart rate, and respiratory rate may occur for physiologic reasons other than pain, and scales using these parameters have failed to show a reproducible measure of pain in the patient who is able to communicate discomfort.
The behavioral pain scale (Table 1) has been used in medical and surgical ICUs and recently investigated in the neuro-ICU for use in intubated and noncommunicative patients. The scale is based on observation of facial expression, upper extremity limb movement, and either ventilator compliance in the intubated patient or vocalization in the nonintubated patent. The measured score ranges from 3 (no pain behavior) to 12 (maximal pain behavior). Although the scale does not correspond directly to severity of pain (ie, mild, moderate, or severe), the trended value has validity for measuring patient discomfort and assessing interventions.
Use of IV opioids is considered fi rst-line management of nonneuropathic pain. The effects of opioids can be divided into two categories: central-analgesia, euphoria, decreased respiratory rate, and mitosis; and peripheral-pruritus, urinary retention, fl ushing, altered gut motility, decreased blood pressure, and heart rate. The use of a concomitant antagonist such as methylnaltrexone, which does not cross the blood-brain barrier, may mitigate some of the peripheral side effects of narcotic usage.
Although there is no clinical research that demonstrates the superiority of one opioid agent over another, several aspects of pain management must be kept in mind. First, long-term use of opioids is associated with a high rate of posthospital dependence. In patients receiving narcotics for more than 7 days after surgery, more than 44% are at risk for long-term use of narcotics. Second, some opioids, particularly hydromorphone and fentanyl, are associated with a higher incidence of opioid-related adverse effects such as severe respiratory depression, for hydromorphone and fentanyl; and dose-dependent chest wall rigidity severe 3 purposeless cognitive and motor activity or restlessness, usually associated with a state of anxiety. Both anxiety and agitation are frequently encountered in the ICU and are associated with adverse outcomes. Although sedatives are frequently administered for control of anxiety and agitation, the potential underlying causes such as pain, hypoxemia, hypoglycemia, hypotension, encephalopathy, intoxicants, and withdrawal from intoxicants should not be disregarded. The goal of anxiety and agitation management should be to address reversible metabolic/physiologic causes, provide for patient comfort, reorient the patient to the environment, optimize normal sleep patterns, and carefully titrate the administration of sedatives.
There are several validated scales for assessing level of sedation in the medical/surgical ICU setting. Although none has been validated in the neuro-ICU, the Richmond Agitation-Sedation Scale (RASS; Table 2 ) has been used in recent neuro-ICU studies. The RASS has also been compared enough to affect spontaneous and mechanical respiration for fentanyl. Third, the rate of opioid-related adverse effects increases with the use of continuous infusions, indicating that intermittent boluses are preferred. Fourth, although morphine is the best-studied agent in the class, all opioids are immune modulators that suppress the phagocytic behavior of macrophages, delay chemotaxis, affect antibody production, and suppress dendritic cells. Whether this leads to an increased risk of infection in the critically ill patient or contributes to morbidity and/or mortality is unknown. The potential adverse effects of opioids have led to interest in other agents to minimize their use. IV formulations of acetaminophen and ibuprofen are available in the United States. Each of these agents has its own potential benefi ts and risks of use. Acetaminophen is contraindicated in patients with compromised hepatic function and should be dosed with caution in patients with a history of chronic alcoholism. Ibuprofen and other nonsteroidal antiinfl ammatory agents are likewise contraindicated in cardiac failure, renal failure, chronic hypertension, and in patents at a high risk of gastric ulceration and/or developing a pseudoarthrosis. Neither drug has been validated in the critical care setting for the management of pain. In patients with a signifi cant amount of neuropathic pain, the use of gabapentin or carbamazepine may be a treatment option.
Anxiety and Agitation
Anxiety is a multisystem response to a perceived threat or danger. It refl ects a combination of biochemical changes in the body, the patient's personal history and memory, and the social situation. Agitation is defined as excessive, The patient has eye opening and eye contact, which is sustained for more than 10 seconds (score −1).
The patient has eye opening and eye contact, but this is not sustained for 10 seconds (score −2).
The patient has any movement in response to voice, excluding eye contact (score −3).
4. If the patient does not respond to voice, physically stimulate the patient by shaking their shoulder and then rubbing sternum. Score as follows:
The patient has any movement to physical stimulation (score −4).
The patient has no response to voice or physical stimulation (score −5).
*Goal sedation level: 0 to −2.
Dexmedetomidine is the newest sedative available in the ICU. The drug is a selective α 2 -receptor agonist that has sedative and analgesic and sympatholytic properties. The most common side effects are profound bradycardia and hypotension, an aspect of drug administration that can be minimized by not using a loading dose before starting a continuous infusion. Dexmedetomidine has no effect on respiratory drive; however, caution and close patient monitoring are important because it can cause signifi cant loss of upper airway muscle tone resulting in obstructive apnea. The drug is highly protein bound and redistributes rapidly in the surrounding tissues. It is cleared by hepatic and renal pathways; therefore, extreme age, decreased glomerular fi ltration rate, and low albumin levels may increase the potency of this drug. The benefi t of using dexmedetomidine is that patients can be aroused easily and interact with caregivers without requiring signifi cant changes in drug dose. Dexmedetomidine is also associated with less delirium than midazolam in a small study. It should be noted that the drug is only approved in the United States for short-term sedation (less than 24 hours), and the doses needed in the neuro-ICU setting may be higher than the manufacture's recommended maximum dose.
Delirium
Delirium is defi ned clinically as an acute change in mental status accompanied by inattention. It may be either hyperactive, consisting of restlessness and agitation, or hypoactive, consisting of lethargy and motor slowing. Although a patient who is delirious may experience hallucinations and/or delusions, their presence is neither common nor necessary to make the diagnosis. The incidence of delirium in the medical/surgical ICU is relatively common (approximately 33% of patients). Incidence increases with age, with approximately 60% of ICU patients over 65 years diagnosed with delirium. The presence of ICU-associated delirium is one of the strongest independent indicators of ICU and hospital length of stay, cost of care, long-term brain function, and survival. Of those surviving to discharge, 50% to 70% will leave with cognitive impairment (mostly executive function and memory) and 60% to 80% with functional impairment. Imaging studies demonstrate that a diagnosis of delirium is associated with posthospitalization atrophy of the frontal lobes and hippocampus on MRI scans obtained 3 months posthospitalization.
The cornerstone of delirium management is prevention. A balance must be reached with adequate analgesia for patient comfort, minimization of sedation, frequent reorientation, early mobilization, normalization of the sleepwake cycle, and monitoring. Several delirium tools are available in the medical/surgical ICU. The intensive care delirium screening checklist (ICDSC ; Table 3 ), has been used in the neuro-ICU for small groups of patients and seems to be implementable and valid. Similar to other tools for pain and sedation monitoring outlined earlier, the ICDSC is based on behavior cues and observations of the sleep-wake cycle, with the exception of inattention and disorientation assessments, which are dependent on language. For patients with diagnosed delirium, antipsychotic agents such as haloperidol and atypical antipsychotics such as with electroencephalographic data obtained from the new generation of bispectral index (BIS) monitor and is roughly correlates with the BIS index of sedation. The RASS is applicable to noncommunicative and brain-injured patients because it relies on behavioral assessment rather than the ability to follow commands. The scores range from +4 (combative) to −5 (unarousable), with a score of 0 corresponding to being awake and alert. Ideal sedation is considered to be a RASS score of 0 to −2.
Unlike opioid medications, for which there is no clinical research to demonstrate the superiority of one agent over the other, several sedatives are available with different receptor targets and resulting pharmacologic properties. Traditional medications used in the neuro-ICU such as thiopental have been supplanted by these drugs. Benzodiazepines such as lorazepam and midazolam bind to the type A γ-aminobutyric acid (GABA A ) receptor. Midazolam is more lipid-soluble, readily crossing the blood-brain barrier, and it has a more rapid onset of action than lorazepam and larger volume of distribution. Midazolam has replaced lorazepam in many institutions for long-term sedation because of the risk of metabolic acidosis caused by the polyethylene glycol contained in IV formulations of lorazepam. All drugs in this class are anxiolytic, amnestic, hypnotic, sedating, anticonvulsant, and cardiopulmonary depressants. Benzodiazepines do not, however, have any analgesic activity, and high doses causing deep sedation cannot be considered as a substitute for pain management. Although a causal relationship cannot be established, the use of benzodiazepines, particularly at high doses for prolonged periods, is associated with increased rates of delirium in the ICU with an associated increase risk of morbidity and mortality.
Propofol is the most widely used drug in the United States. It is known to bind to a variety of receptor types, including GABA A , glycine, nicotinic, and M 1 muscarinic. It has anxiolytic, amnestic, hypnotic, sedating, anticonvulsant, and antiemetic effects and causes dose-dependent respiratory depression and hypotension secondary to peripheral vasodilation. Like benzodiazepines, propofol has no analgesic effect. It is highly lipid soluble and rapidly redistributes into peripheral tissues, giving it rapid onset and rapid offset properties. It is therefore useful in the setting of frequent neurologic examinations such as the neuro-ICU. Compared with benzodiazepines, propofol is associated with lower rates of delirium in medical/surgical ICUs. Long-term propofol infusion is not without risk. Tissue saturation can cause prolonged emergence times. The drug is delivered in a 10% lipid emulsion, which at high doses over prolonged periods may cause hypertriglyceridemia and acute pancreatitis. Propofol is also immunosuppressive, inhibiting neutrophil degranulation, chemotaxis, and cytokine release. Administration of propofol may also cause propofol infusion syndrome, which may occur after brief exposure at relatively low doses of the drug. The syndrome consists of a worsening metabolic acidosis with increasing requirements for vasopressor support, accompanying cardiac arrhythmias, and possible associated renal injury, hyperkalemia, rhabdomyolysis, and/or hepatic dysfunction.
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quetiapine have been used. There are no randomized clinical trials to support the use of these agents in the ICU setting, with only small case control studies for guidance.
Recommendations
Management of pain, anxiety, and agitation and prevention of delirium require a coordinated, multidisciplinary effort involving nurses, respiratory therapists, pharmacists, and physicians. A basic ABCCDE approach has been advocated by the Society for Critical Care Medicine. ABC stands for awake, breath, and coordinate. In stable patients who are mechanically intubated, trials of spontaneous removal of sedation, accompanied by spontaneous breathing trials, decrease the duration of mechanical ventilation, decrease the duration of medically induced coma, and decrease mortality. C is choice of drug; minimal sedation and careful drug selection have been demonstrated to decrease the duration of mechanical ventilation, decrease the rate of delirium, and decrease mortality rates. D is routine delirium monitoring and management emphasizing prevention. E is early mobilization and optimization of patient environment; the ICU is a noisy and chaotic environment for patients, and noise minimization, optimization of patient sleep-wake cycles, and early mobilization will decrease the risk of delirium. *The patient is to be scored for agitation over the entire shift (8 hours). Individual components of the score do not need to be present simultaneously. †Item numbers 1 through 4 require that the patient not be deeply sedated or comatose. ‡Item numbers 5 and 6 are based on shift observation. §Item numbers 7 and 8 are based on 24-hour observation.
Readings

Score classifi cation:
0 Normal.
1-3 Subsyndromal delirium.
4-8 Delirium.
1. A combined ICU protocol of daily spontaneous breathing trials with spontaneous awakening trials will decrease the median ICU length stay in a medical/surgical population.
True or False?
2. Clinical evidence has demonstrated that the most effective predictor of successful weaning from mechanical intubation and extubation is a combined RN/RT protocol.
3. A 23-year-old man is involved as an unhelmeted rider in a motorcycle-automobile collision at city street speeds. He has a Glasgow Coma Scale score of 8 [E2V(T)M5] at presentation, with a small amount of convexity; subarachnoid hemorrhage on head CT; and minimal diffuse axonal injury, with cisterns open. He is intubated for airway control in the setting of midface fractures, and an extraventricular drain is placed for monitoring with low opening pressures. He also has sustained several rib fractures with a resulting right pneumothorax, and a chest tube is placed. You are called to bedside by the nurse because the patient is agitated and bucking the ventilator. The patient's ICP is greater than 20 mm Hg. He has a clear facial grimace and fl exed upper extremity posture. The best agent for management of this patient is mannitol.
4. The most effective method of assessing pain in the intubated patient is a combination of heart rate, blood pressure, and respiratory rate.
5. Using the RASS, a patient who is awake and calm has a score of 0.
6. Hallucinations are the most commonly observed symptom of delirium in the ICU.
7. The most commonly observed side effects of dexmedetomidine administration are hypotension and bradycardia.
8. The most prominent feature of propofol infusion is myoclonus.
9. When using the intensive care delirium screening checklist, the section on inattention is dependent on assessing language.
10. Fentanyl may cause dose-independent chest wall rigidity.
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